[Effects of concurrent therapy for patients with osteoporosis].

Abstract

In the WHO technical report, vitamin D metabolites have been suggested to have a role as an adjunctive therapy when given with an antiresorptive agent. Beneficial effects on BMD have been reported following the addition of calcitriol to alendronate, etidronate, and HRT, but no data on fracture rates are available. Here we summarize our clinical study on the concurrent therapy and review reports on the concurrent treatments.

• Authors: Seneki Kobayashi, Masataka Shiraki, Kunio Takaoka
• Journal: Clinical calcium (Clin Calcium) Vol. 15 Issue 4 Pg. 661-5 (Apr 2005) ISSN: 0917-5857 [Print] Japan
• PMID: 15802781 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Diphosphonates
• Vitamin K 2
• Cholecalciferol
• Etidronic Acid

Topics

• Aged
• Bone Density
• Cholecalciferol (administration & dosage)
• Clinical Trials as Topic
• Diphosphonates (administration & dosage)
• Drug Therapy, Combination
• Estrogen Replacement Therapy
• Etidronic Acid (administration & dosage)
• Female
• Fractures, Bone (prevention & control)
• Humans
• Male
• Multicenter Studies as Topic
• Osteoporosis (drug therapy, metabolism, prevention & control)
• Vitamin K 2 (administration & dosage)